Lantheus Holdings Inc. (LNTH) Upgraded to “Buy” at Zacks Investment Research
Zacks Investment Research upgraded shares of Lantheus Holdings Inc. (NASDAQ:LNTH) from a hold rating to a buy rating in a research report report published on Wednesday morning. They currently have $9.00 price objective on the stock.
According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “
Several other equities research analysts have also weighed in on the stock. Jefferies Group upped their target price on shares of Lantheus Holdings from $8.00 to $12.00 and gave the stock a buy rating in a report on Monday, August 29th. Credit Suisse Group AG set a $4.00 target price on shares of Lantheus Holdings and gave the stock a hold rating in a report on Friday, August 5th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of $7.80.
Shares of Lantheus Holdings (NASDAQ:LNTH) opened at 8.45 on Wednesday. The company has a 50 day moving average of $8.49 and a 200-day moving average of $4.75. Lantheus Holdings has a 12-month low of $1.76 and a 12-month high of $10.10. The company has a market capitalization of $256.77 million, a P/E ratio of 9.54 and a beta of 0.47.
Lantheus Holdings (NASDAQ:LNTH) last posted its earnings results on Thursday, August 4th. The company reported $0.24 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.18. Lantheus Holdings had a net margin of 9.00% and a negative return on equity of 11.75%. The business had revenue of $78 million for the quarter, compared to analyst estimates of $72.66 million. On average, equities analysts anticipate that Lantheus Holdings will post $0.55 EPS for the current fiscal year.
Large investors have recently modified their holdings of the company. BlackRock Institutional Trust Company N.A. raised its stake in shares of Lantheus Holdings by 28.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 194,308 shares of the company’s stock worth $367,000 after buying an additional 42,971 shares in the last quarter. Spark Investment Management LLC raised its stake in shares of Lantheus Holdings by 541.2% in the first quarter. Spark Investment Management LLC now owns 106,100 shares of the company’s stock worth $200,000 after buying an additional 89,553 shares in the last quarter. State Street Corp raised its stake in shares of Lantheus Holdings by 10.3% in the first quarter. State Street Corp now owns 106,233 shares of the company’s stock worth $200,000 after buying an additional 9,909 shares in the last quarter. Gabelli Funds LLC raised its stake in shares of Lantheus Holdings by 22.2% in the second quarter. Gabelli Funds LLC now owns 165,000 shares of the company’s stock worth $606,000 after buying an additional 30,000 shares in the last quarter. Finally, GSA Capital Partners LLP raised its stake in shares of Lantheus Holdings by 3.7% in the second quarter. GSA Capital Partners LLP now owns 154,322 shares of the company’s stock worth $566,000 after buying an additional 5,500 shares in the last quarter. 30.15% of the stock is currently owned by hedge funds and other institutional investors.
About Lantheus Holdings
Lantheus Holdings, Inc develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.